Syndax Pharmaceuticals Inc (NAS:SNDX)
$ 20.28 0.17 (0.85%) Market Cap: 1.72 Bil Enterprise Value: 1.28 Bil PE Ratio: 0 PB Ratio: 3.50 GF Score: 53/100

Syndax Pharmaceuticals Inc at Barclays Global Healthcare Conference Transcript

Mar 16, 2022 / 07:50PM GMT
Release Date Price: $17.07 (+6.16%)
Peter Richard Lawson
Barclays Bank PLC, Research Division - Research Analyst

First and foremost, for all those in the audience and listening on the webcam on the presentation. It's a pleasure to have everyone back in person, management, investors, et cetera. So it's fantastic to having your support and enthusiasm for this event after 2 years, we're kind of coming back to norm, and my name is Peter Lawson. I'm 1 of the biotech analysts. I'll be hosting this fireside chat with Syndax. And I just want to thank Michael Metzger, CEO from Syndax. And I guess the first thing, I think, Michael, you can just talk through the kind of corporate overview, maybe of how you differentiate within the space and how the year has been for Syndax.

Michael A. Metzger;Peter
Syndax Pharmaceuticals, Inc. - CEO & Director

Yes. Well, first of all, thank you, Peter. Thanks to Barclays for inviting us to speak today, and it's nice to be back in person finally after 2 years of doing Zoom meetings. But let me first start off. Do we have the slides? Corporate didn't...

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot